Projects per year
Fingerprint
Dive into the research topics where Sandra Tuyaerts is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
OZR3913: Cofinancing OZR FWO Hercules MZW - High-parametric single-cell protein profiling in intact tissues
Movahedi, K., van Grunsven, L., Rooman, I., Van Ginderachter, J., Smolders, I., Neyns, B., Vanhaecke, T., Laoui, D., Breckpot, K., De Veirman, K., Stijlemans, B., Van Schependom, J., Magez, S., Goyvaerts, C., De Kock, J., De Leu, N., Massie, A., Hellemans, K., Spits, C., De Bundel, D., De Trez, C., Hernot, S., Van Dooren, S., Aerts, J., Staels, W. & Tuyaerts, S.
25/02/22 → 25/02/26
Project: Fundamental
Research output
-
159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma
De Jaeghere, E., Tuyaerts, S., Van Nuffel, A., Lippens, L., Hendrix, A., Vuylsteke, P., trinh, X. B., Van Dam, P. A., Aspeslagh, S., De Caluwé, A., Naert, E., Van de Vijver, K., Amant, F., Vandecasteele, K. & Denys, H., Dec 2021, In : Annals of Oncology. 32, suppl 7, p. 1449-1450 2 p.Research output: Contribution to journal › Article
Open Access -
Abstract 962MO. A phase I clinical trial on intratumoral injection of autologous CD1C (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Dufait, I., Forsyth, R., Van Riet, I., Tuyaerts, S. & Neyns, B., 1 Sep 2021, In : Annals of Oncology. 32, p. S832-S833Research output: Contribution to journal › Meeting abstract (Journal)
-
Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
Baiden-Amissah, R. E. M., Annibali, D., Tuyaerts, S. & Amant, F., 7 Aug 2021, In : Cancers. 13, 16, 17 p., 3988.Research output: Contribution to journal › Article
Open Access3 Citations (Scopus) -
INTRA-CRANIAL ADMINISTRATION OF CTLA-4 AND PD-1 IMMUNE CHECKPOINT-INHIBITING MONOCLONAL ANTIBODIES IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTI-COHORT ADAPTIVE PHASE I CLINICAL TRIAL
Duerinck, J., Geens, W., Schwarze, J. K., Bertels, C., Tijtgat, J., Awada, G., Vaeyens, F., Cras, L., Nijland, L., Vanbinst, A-M., Everaert, H., Michotte, A., Janssen, T., Caljon, B., Cauwenbergh, T., Bruneau, M., Forsyth, R., Tuyaerts, S. & Neyns, B., Nov 2021, In : Journal for immunotherapy of cancer. 9, 6, p. 53-53 1 p.Research output: Contribution to journal › Article
Open Access8 Citations (Scopus) -
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
De Wispelaere, W., Annibali, D., Tuyaerts, S., Lambrechts, D. & Amant, F., 1 May 2021, In : Cancers. 13, 9, 15 p., 2040.Research output: Contribution to journal › Article
Open Access3 Citations (Scopus)
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor)17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
Human relevant models for drug research and development
Fien Meeus (Speaker), Robin Maximilian Awad (Contributor), Nick Devoogdt (Contributor), Sandra Tuyaerts (Contributor), Cleo Goyvaerts (Contributor), Yannick De Vlaeminck (Contributor), Bart Neyns (Contributor), Karine Breckpot (Contributor)8 Oct 2021Activity: Talk or presentation › Talk or presentation at a workshop/seminar